AstraZeneca PLC (AZN) vs Bristol-Myers Squibb Company (BMY)
AZN leads on 11 of 17 compared metrics.
A side-by-side comparison of AstraZeneca PLC and Bristol-Myers Squibb Company across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 13, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
Total return — AZN vs BMY
growth of $100 · last 30yAZN +658.3%BMY +171.3%AZN compounded faster
AZN BMY
AZN vs BMY: by the numbers
- •AZN is the larger company ($131.41B vs $121.18B market cap).
- •AZN trades at the lower earnings multiple (12.92 vs 16.17 P/E).
- •AZN converts more revenue to profit (17.19% vs 15.01% net margin).
- •AZN grew revenue faster over the past five years (16.99% vs 2.52% CAGR).
- •BMY pays the higher dividend yield (4.38% vs 2.53%).
Which is better, AZN or BMY?
Metric tally: AZN 11 · BMY 6It depends on what you're optimizing for:
ValueAZN(lower P/E)
GrowthAZN(faster 5Y revenue CAGR)
IncomeBMY(higher dividend yield)
QualityBMY(higher ROIC)
Metrics side by side
Valuation
| Metric | AZN | BMY |
|---|---|---|
| P/E ratio | 12.92● | 16.17 |
| Forward P/E | 16.75 | 9.10● |
| P/S ratio | 2.22● | 2.43 |
| P/B ratio | 2.83● | 5.86 |
| PEG ratio | 0.29● | 1.72 |
| EV / EBITDA | 7.96● | 9.70 |
| FCF yield | 6.02% | 10.12%● |
Profitability
| Metric | AZN | BMY |
|---|---|---|
| Gross margin | 81.68%● | 68.75% |
| Operating margin | 23.69% | 25.67%● |
| Net margin | 17.19%● | 15.01% |
| ROE | 21.95% | 36.25%● |
| ROIC | 13.03% | 13.90%● |
Dividends
| Metric | AZN | BMY |
|---|---|---|
| Dividend yield | 2.53% | 4.38%● |
| Payout ratio | 32.88% | 72.83% |
Growth (annualized)
| Metric | AZN | BMY |
|---|---|---|
| Revenue CAGR (5Y) | 16.99%● | 2.52% |
| EPS CAGR (5Y) | 22.02%● | 9.38% |
| FCF CAGR (5Y) | 15.68%● | -2.50% |
| Total return CAGR (5Y) | 9.07%● | 1.02% |
Frequently asked
- Which is better, AZN or BMY?
- It depends on your goal. value: AZN (lower P/E); growth: AZN (faster 5Y revenue CAGR); income: BMY (higher dividend yield); quality: BMY (higher ROIC). Across all compared metrics, AZN leads 11 to 6.
- Is AZN or BMY cheaper?
- On trailing earnings, AZN is cheaper: AZN trades at a 12.92 P/E and BMY at 16.17.
- Which has grown faster, AZN or BMY?
- Over the past five years, AZN grew revenue faster — AZN at a 16.99% CAGR versus BMY at 2.52%.
- Does AZN or BMY pay a bigger dividend?
- AZN yields 2.53% and BMY yields 4.38% based on trailing dividends and the latest price.
- Is AZN or BMY more profitable?
- AZN runs the higher net margin — AZN at 17.19% versus BMY at 15.01%.
- Which has been the better investment, AZN or BMY?
- Over the past 10-year, AZN delivered the higher annualized total return — AZN at 14.21% versus BMY at 0.85%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
AstraZeneca P/E ratioBristol-Myers Squibb P/E ratioAstraZeneca dividend yieldBristol-Myers Squibb dividend yieldAstraZeneca ROEBristol-Myers Squibb ROEAstraZeneca operating marginBristol-Myers Squibb operating marginAstraZeneca revenue growthBristol-Myers Squibb revenue growthAstraZeneca free cash flowBristol-Myers Squibb free cash flow
AstraZeneca & Bristol-Myers Squibb appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 13, 2026.